Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · Real-Time Price · USD
1.170
-0.060 (-4.88%)
At close: Apr 1, 2025, 4:00 PM
1.200
+0.030 (2.56%)
After-hours: Apr 1, 2025, 4:29 PM EDT
Iterum Therapeutics Employees
Iterum Therapeutics had 9 employees as of December 31, 2024. The number of employees decreased by 5 or -35.71% compared to the previous year.
Employees
9
Change (1Y)
-5
Growth (1Y)
-35.71%
Revenue / Employee
n/a
Profits / Employee
-$2,752,667
Market Cap
40.46M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ITRM News
- 7 weeks ago - Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025 - GlobeNewsWire
- 4 months ago - Iterum Therapeutics Regains Full Nasdaq Compliance - GlobeNewsWire
- 4 months ago - Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Iterum Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 5 months ago - Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript) - Seeking Alpha
- 5 months ago - Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - PRNewsWire